AR035842A1 - Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo - Google Patents

Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo

Info

Publication number
AR035842A1
AR035842A1 ARP000102308A ARP000102308A AR035842A1 AR 035842 A1 AR035842 A1 AR 035842A1 AR P000102308 A ARP000102308 A AR P000102308A AR P000102308 A ARP000102308 A AR P000102308A AR 035842 A1 AR035842 A1 AR 035842A1
Authority
AR
Argentina
Prior art keywords
ring
intermediary
compounds
keto
group
Prior art date
Application number
ARP000102308A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911345.8A external-priority patent/GB9911345D0/en
Priority claimed from GBGB9918178.6A external-priority patent/GB9918178D0/en
Priority claimed from GBGB9923632.5A external-priority patent/GB9923632D0/en
Priority claimed from GB0001063A external-priority patent/GB0001063D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of AR035842A1 publication Critical patent/AR035842A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Se trata de un método para preparar compuestos de estructura de anillos fusionado de fórmula (1) que comprende una o más reacciones a partir de un compuesto 21-ciano de la fórmula (2), en donde generalmente: R1 es un grupo amidometileno o un grupo aciloximetileno. R5 y R8 son independientemente seleccionados entre -H, -OCOCH2OH, o R5 y R8 son ambos ceto y el anillo A es un anillo p-benzoquinona; R14a y R14b son ambos -H o uno es -H y el otro es -OH, -OCH3, o -OCH2CH3 o R14b y R14a juntos forman un grupo ceto, y R15 y R18 son independientemente seleccionados entre -H, o -OH o R5 y R8 son ambos ceto y el anillo A es un anillo p-benzoquinona. También se proponen y reivindican compuestos intermediarios de fórmula (2) en donde: R1 es un grupo amidometileno o un grupo aciloximetileno. R5 y R8 son independientemente seleccionados entre -H, -OCOCH2OH, o R5 y R8 son ambos ceto y el anillo A es un anillo p-benzoqinona. R14a y R14b son ambos -H o uno es H y el otro es -OH, -OCH3, o -OCH2CH3 o R14b y R14a juntos forman un grupo ceto, y R15 y R18 son independientemente seleccionados entre -H, o -OH o R5 y R8 son ambos ceto y el anillo A es un anillo p-benzoquinona, con la excepción de safracina B.
ARP000102308A 1999-05-14 2000-05-12 Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo AR035842A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9911345.8A GB9911345D0 (es) 1999-05-14 1999-05-14
GBGB9918178.6A GB9918178D0 (en) 2000-05-15 1999-08-02 Synthetic methods
GBGB9923632.5A GB9923632D0 (en) 1999-10-06 1999-10-06 Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB0001063A GB0001063D0 (en) 2000-01-17 2000-01-17 Hemisynthetic process towards ecteinascidin and phtalascidin

Publications (1)

Publication Number Publication Date
AR035842A1 true AR035842A1 (es) 2004-07-21

Family

ID=42632476

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102308A AR035842A1 (es) 1999-05-14 2000-05-12 Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo

Country Status (30)

Country Link
US (3) US7241892B1 (es)
EP (1) EP1185536B1 (es)
JP (1) JP4445136B2 (es)
KR (1) KR100834601B1 (es)
CN (3) CN1229382C (es)
AR (1) AR035842A1 (es)
AT (1) ATE283273T1 (es)
AU (2) AU775580B2 (es)
BG (1) BG65896B1 (es)
BR (3) BRPI0010559B8 (es)
CA (2) CA2372058C (es)
CY (1) CY1108095T1 (es)
CZ (3) CZ303536B6 (es)
DE (1) DE60016209T2 (es)
DK (1) DK1185536T3 (es)
ES (2) ES2233367T3 (es)
HK (1) HK1047432A1 (es)
HU (1) HU230646B1 (es)
MX (1) MXPA01011631A (es)
MY (1) MY130271A (es)
NO (2) NO322016B1 (es)
NZ (1) NZ515424A (es)
PL (1) PL226890B1 (es)
PT (1) PT1185536E (es)
RU (1) RU2237063C9 (es)
SI (2) SI1185536T1 (es)
SK (2) SK287835B6 (es)
TR (1) TR200103273T2 (es)
UA (1) UA75333C2 (es)
WO (3) WO2000069862A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003470T2 (tr) 1998-05-11 2001-06-21 Pharama Mar, S.A. Ecteinascidin 743 Metabolitleri
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
DE60111845T2 (de) * 2000-04-12 2006-04-27 Pharma Mar, S.A., Tres Cantos Ecteinaschidin derivate mit antikrebs wirkung
JP4942900B2 (ja) * 2000-05-15 2012-05-30 ファルマ・マール・ソシエダード・アノニマ エクチナサイジン化合物の製造のための合成方法
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
WO2002040477A2 (en) 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
JP4391083B2 (ja) * 2000-11-06 2009-12-24 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
WO2003039571A1 (en) * 2001-10-19 2003-05-15 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 (en) 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) * 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
US20090117176A1 (en) * 2004-10-26 2009-05-07 Pharma Mar, S.A. Sociedad Unipersonal Anticancer Treatments
RU2382647C2 (ru) * 2004-10-29 2010-02-27 Фарма Мар С.А., Сосьедад Униперсональ Композиции, содержащие эктинэсайдин и дисахарид
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR100712667B1 (ko) 2006-04-11 2007-05-02 재단법인서울대학교산학협력재단 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
CA2724325A1 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
JP2011520846A (ja) * 2008-05-16 2011-07-21 ファルマ・マール・ソシエダード・アノニマ 多発性骨髄腫の治療
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
CA2800097C (en) 2010-05-25 2019-01-08 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds and intermediates
LT2786753T (lt) 2010-11-12 2019-04-10 Pharma Mar S.A. Derinių terapija su antinavikiniu antibiotiku
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107739387B (zh) * 2017-10-16 2020-01-03 上海皓元生物医药科技有限公司 一种制备曲贝替定的关键中间体化合物的方法
CN109912629B (zh) * 2017-12-13 2021-12-24 浙江中科创越药业有限公司 天然产物Trabectedin的制备
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN111518110B (zh) * 2019-02-01 2023-11-03 博瑞生物医药（苏州）股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN111620792B (zh) * 2019-02-28 2023-01-03 兰州大学 一种n,n-二取代氰基甲酰胺的合成方法
CN116217584A (zh) * 2021-12-06 2023-06-06 南通诺泰生物医药技术有限公司 Et743及其中间体的光催化合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461995A1 (fr) * 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6054386A (ja) * 1983-09-02 1985-03-28 Yoshitomi Pharmaceut Ind Ltd サフラシン誘導体
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
AU589282B2 (en) 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4443043B2 (ja) * 1998-04-06 2010-03-31 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ 半合成エクテイナシジン
TR200003470T2 (tr) 1998-05-11 2001-06-21 Pharama Mar, S.A. Ecteinascidin 743 Metabolitleri
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US6686470B2 (en) 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
DE60111845T2 (de) 2000-04-12 2006-04-27 Pharma Mar, S.A., Tres Cantos Ecteinaschidin derivate mit antikrebs wirkung
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
SK287835B6 (sk) 2011-12-05
MY130271A (en) 2007-06-29
BRPI0110443B8 (pt) 2021-05-25
BRPI0110801B1 (pt) 2018-02-27
CZ304973B6 (cs) 2015-02-25
KR100834601B1 (ko) 2008-06-02
RU2237063C9 (ru) 2008-10-10
NO328301B1 (no) 2010-01-25
ATE283273T1 (de) 2004-12-15
EP1185536A2 (en) 2002-03-13
PL353002A1 (en) 2003-09-22
CZ303536B6 (cs) 2012-11-21
CN100475822C (zh) 2009-04-08
CZ20023751A3 (en) 2004-05-12
AU5649601A (en) 2001-11-26
HUP0201188A2 (en) 2002-07-29
DK1185536T3 (da) 2005-04-04
SK15272002A3 (sk) 2003-06-03
CA2372058A1 (en) 2000-11-23
CN1360588A (zh) 2002-07-24
CN1211386C (zh) 2005-07-20
WO2000069862A3 (en) 2001-03-22
JP4445136B2 (ja) 2010-04-07
BG65896B1 (bg) 2010-04-30
JP2002544280A (ja) 2002-12-24
CA2406095C (en) 2010-02-16
US20040002602A1 (en) 2004-01-01
BR0110801A (pt) 2003-02-11
CN1440414A (zh) 2003-09-03
DE60016209D1 (de) 2004-12-30
NZ515424A (en) 2004-06-25
US7524956B2 (en) 2009-04-28
BR0110443A (pt) 2003-04-08
SK287879B6 (sk) 2012-02-03
WO2001087894A1 (en) 2001-11-22
CY1108095T1 (el) 2014-02-12
DE60016209T2 (de) 2005-12-15
BRPI0010559B1 (pt) 2016-08-30
SI1287004T1 (sl) 2005-12-31
BG107301A (bg) 2003-07-31
US7241892B1 (en) 2007-07-10
ES2233367T3 (es) 2005-06-16
PL226890B1 (pl) 2017-09-29
CA2406095A1 (en) 2001-11-22
UA75333C2 (uk) 2006-04-17
PT1185536E (pt) 2005-04-29
MXPA01011631A (es) 2002-07-30
CA2372058C (en) 2010-10-26
NO20015547L (no) 2002-01-14
AU4597300A (en) 2000-12-05
NO20025186D0 (no) 2002-10-29
CZ20023746A3 (cs) 2003-04-16
SI1185536T1 (en) 2005-06-30
TR200103273T2 (tr) 2002-04-22
WO2000069862A2 (en) 2000-11-23
SK16502001A3 (sk) 2002-06-04
RU2237063C2 (ru) 2004-09-27
EP1185536B1 (en) 2004-11-24
WO2001087895A1 (en) 2001-11-22
BR0010559A (pt) 2002-07-02
CZ304966B6 (cs) 2015-02-18
BRPI0010559B8 (pt) 2021-05-25
US20080045713A1 (en) 2008-02-21
BRPI0110443B1 (pt) 2018-06-26
ES2231486T3 (es) 2005-05-16
BRPI0110801B8 (pt) 2021-05-25
HU230646B1 (hu) 2017-05-29
NO20015547D0 (no) 2001-11-13
HK1047432A1 (en) 2003-02-21
NO322016B1 (no) 2006-08-07
KR20020021636A (ko) 2002-03-21
CN1229382C (zh) 2005-11-30
CN1441805A (zh) 2003-09-10
AU775580B2 (en) 2004-08-05
CZ20014102A3 (cs) 2002-06-12
NO20025186L (no) 2003-01-14

Similar Documents

Publication Publication Date Title
AR035842A1 (es) Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
DK446279A (da) Fremgangsmaade til fremstilling af substituerede 1-carba-2-penem-3-carboxylsyrer
AR031828A2 (es) Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia
UY25682A1 (es) Procedimiento para preparar derivados de quinolin-2-ona alquinilsustituidos útiles como agentes anticancerosos entre otras acciones terapéuticas
CY1105719T1 (el) Νεα κινουκλιδινικα παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
PE20011373A1 (es) Derivados de tiofeno de formula (i)
KR920008063A (ko) 전립선 이상비대 치료용 아자스테로이드 화합물, 그것의 제조방법 및 용도
CY1105035T1 (el) Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
CO4950563A1 (es) Nuevos compuestos
AR028531A1 (es) Compuestos organicos
ATE28872T1 (de) Neue imidazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
KR950032267A (ko) 11,21-비스페닐-19-노르프레그난 유도체
SE9703377D0 (sv) New compounds
AR030143A1 (es) Compuestos de ciclohexilo 1,4-sustituidos, usos de dichos compuestos para la manufactura de medicamentos, compuestos isotopicamente rotulados, agente de diagnostico, composiciones farmaceuticas, proceso para la preparacion de dichos compuestos, compuestos intermediarios para su uso exclusivo en el p
ES425626A1 (es) Un procedimiento para preparar compuestos de acil-xilidida.
NO20001871L (no) Nye 3,6-hemiacetaler fra klassen 9a-azalider
AR002300A1 (es) Compuestos heteroarilpiperazinas particularmente utiles como agentes antipsicoticos, composiciones, procedimientos par la preparacion y metodosterapeuticos de utilizacion de dichos compuestos.
BG103207A (en) Esters of the arylcycloalkanecarboxylic acids, their application, pharmaceutical compositions and their preparation
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
KR880011122A (ko) 4-티오퀴나졸린 유도체, 이의 제조방법 및 약제학적 조성물
GB1057349A (en) Water-soluble flavanoid derivatives
DE60043293D1 (de) VAKUOLAR-TYP (H+)-ATPase-HEMMENDE VERBINDUNGEN, ZUSAMMENSETZUNGEN UND DEREN VERWENDUNGEN
HUT49613A (en) Process for producing new 8-aza-1,4-dioxaspiro/4,5/decan-2-ylmethyl ester derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acids and pharmaceutical compositions comprising same
EA200101170A1 (ru) Галоидпроизводные 9-деоксо-9а-аза-9а-гомоэритромицина а

Legal Events

Date Code Title Description
FG Grant, registration